Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicoderm in Canada

This article was originally published in The Tan Sheet

Executive Summary

Patented Medicine Prices Review Board will hold a hearing on the price of the nicotine patch marketed by Hoechst Marion Roussel Canada. The purpose of the hearing, scheduled for July 5, is to try to determine whether HMR has sold or is selling, anywhere in Canada, Nicoderm at a price the board considers "excessive," and if so, "what order, if any, should be made." The PRPMB, a quasi-judicial body, was created in 1987 to ensure that patented drug prices are not excessive, to report annually to Parliament on price trends and the ratio of R&D expenditures to sales. Nicoderm was cleared for self-selection in Canada in 1998. For information on the hearing, contact PMPRB's Sylvie Dupont-Kirby at 877-861-2350
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel